Regeneron Pharmaceuticals (REGN) Cash & Current Investments (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Cash & Current Investments of $8.0 billion for Q2 2026, up 7.03% year-over-year from $7.5 billion in Q2 2025, and down 8.67% quarter-over-quarter from $8.8 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Cash & Current Investments (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $8.0 billion for Q2 2026.
- In Q2 2026, Cash & Current Investments rose 7.03% year-over-year to $8.0 billion; the TTM figure through Jun 2026 stood at $8.0 billion (up 7.03% YoY), while the FY2025 annual figure was $8.6 billion, down 4.52% from the prior year.
- Cash & Current Investments for Q2 2026 stood at $8.0 billion, down from $8.8 billion in the prior quarter.
- The five-year high for Cash & Current Investments was $10.8 billion in Q4 2023, with the low at $7.0 billion in Q3 2022.
- The 5-year median for Cash & Current Investments is $8.7 billion (2025), against an average of $8.7 billion.
- The sharpest annual moves came in 2022 and 2025: Cash & Current Investments soared 101.23% in 2022, then dropped 23.85% in 2025.
- Regeneron Pharmaceuticals' Cash & Current Investments stood at $7.7 billion in 2022, then soared by 40.07% to $10.8 billion in 2023, then slipped by 16.9% to $9.0 billion in 2024, then decreased by 4.52% to $8.6 billion in 2025, then fell by 7.1% to $8.0 billion in 2026.
- Business Quant data shows REGN's Cash & Current Investments at $8.0 billion in Q2 2026, $8.8 billion in Q1 2026, and $8.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.99 Bn |
| Mar 31, 2026 | 8.75 Bn |
| Dec 31, 2025 | 8.61 Bn |
| Sep 30, 2025 | 8.44 Bn |
| Jun 30, 2025 | 7.47 Bn |
| Mar 31, 2025 | 8.35 Bn |
| Dec 31, 2024 | 9.01 Bn |
| Sep 30, 2024 | 9.80 Bn |
| Jun 30, 2024 | 9.81 Bn |
| Mar 31, 2024 | 10.52 Bn |
| Dec 31, 2023 | 10.84 Bn |
| Sep 30, 2023 | 9.91 Bn |
| Jun 30, 2023 | 8.93 Bn |
| Mar 31, 2023 | 8.96 Bn |
| Dec 31, 2022 | 7.74 Bn |
| Sep 30, 2022 | 7.02 Bn |
| Jun 30, 2022 | 7.57 Bn |
| Mar 31, 2022 | 7.05 Bn |
| Dec 31, 2021 | 5.69 Bn |
| Sep 30, 2021 | 5.79 Bn |